Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | NAAA | Q02083 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | IDH1 | O75874 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | USP19 | O94966 | 1/20 | 0.40 |
| ▸ | DAGLA | Q9Y4D2 | 2/20 | 0.39 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.39 |
| ▸ | KLK7 | P49862 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1189230 | 1.00 | LMNA (0.48) | LMNAMAPK1SMN1; SMN2NAAAALDH1A1 | |
| SCHEMBL4189285 | 1.00 | LMNA (0.48) | LMNAMAPK1SMN1; SMN2NAAAALDH1A1 | |
| SCHEMBL3637332 | 0.99 | LMNA (0.47) | LMNAMAPK1SMN1; SMN2NAAAALDH1A1 | |
| SCHEMBL9743493 | 0.99 | LMNA (0.47) | LMNAMAPK1SMN1; SMN2NAAAALDH1A1 | |
| SCHEMBL9557087 | 0.99 | LMNA (0.47) | LMNAMAPK1SMN1; SMN2NAAAALDH1A1 | |
| SCHEMBL9743484 | 0.99 | LMNA (0.47) | LMNAMAPK1SMN1; SMN2NAAAALDH1A1 | |
| SCHEMBL3773685 | 0.99 | LMNA (0.47) | LMNAMAPK1SMN1; SMN2NAAAALDH1A1 | |
| SCHEMBL19814964 | 0.98 | NAAA (0.46) | LMNAMAPK1SMN1; SMN2NAAAALDH1A1 | |
| SCHEMBL7495438 | 0.98 | NAAA (0.46) | LMNAMAPK1SMN1; SMN2NAAAALDH1A1 | |
| SCHEMBL15443176 | 0.95 | NAAA (0.48) | LMNAMAPK1SMN1; SMN2NAAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107032992-A | A kind of synthetic method of (R) 4 (tert-butoxy) 2 (cyclopentyl-methyl) 4 ketobutyric acid | 华东师范大学 | 2017-08-11 | — | — | CN | disclosed |
| WO-2011151434-A1 | NOVEL COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS | EUROSCREEN S.A. (BE) | 2011-12-08 | — | — | WO | disclosed |
| US-20090111793-A1 | HYDROXYALKANOYLAMINOLACTAMS AND RELATED STRUCTURES AS INHIBITORS OF A BETA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2009-04-30 | — | — | US | disclosed |
| US-20090111793-A1 | HYDROXYALKANOYLAMINOLACTAMS AND RELATED STRUCTURES AS INHIBITORS OF A BETA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2009-04-30 | — | — | US | disclosed |
| US-7423033-B2 | Hydroxyalkanoylaminolactams and related structures as inhibitors of aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-09-09 | — | — | US | disclosed |
| US-7423033-B2 | Hydroxyalkanoylaminolactams and related structures as inhibitors of aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-09-09 | — | — | US | disclosed |
| US-20080132482-A1 | HYDROXYALKANOYLAMINOLACTAMS AND RELATED STRUCTURES AS INHIBITORS OF A BETA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-06-05 | — | — | US | disclosed |
| US-20080132482-A1 | HYDROXYALKANOYLAMINOLACTAMS AND RELATED STRUCTURES AS INHIBITORS OF A BETA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-06-05 | — | — | US | disclosed |
| US-7342008-B2 | Containing a benzodiazepine ring; 2-Cyclopentylmethyl-3(S)-hydroxyl-1-oxo-5-phenylpentyl)amino-1-methyl-5-(4-fluoro-phenyl)-2,3-dihydro-1H-1,5-benzodiazepin-2-one; Alzheimer's disease and Down's Syndrome; prevent the formation of neurological deposits of amyloid protein | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-03-11 | — | — | US | disclosed |
| US-7342008-B2 | Containing a benzodiazepine ring; 2-Cyclopentylmethyl-3(S)-hydroxyl-1-oxo-5-phenylpentyl)amino-1-methyl-5-(4-fluoro-phenyl)-2,3-dihydro-1H-1,5-benzodiazepin-2-one; Alzheimer's disease and Down's Syndrome; prevent the formation of neurological deposits of amyloid protein | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-03-11 | — | — | US | disclosed |
| US-20030166636-A1 | Hydroxyalkanoylaminolactams and related structures as inhibitors of A-beta protein production | OLSON RICHARD E (US) | 2003-09-04 | — | — | US | disclosed |
| EP-1052249-B1 | Process for the preparation of hydroxamic acids | HOFFMANN LA ROCHE (CH) | 2003-08-13 | — | — | EP | disclosed |
| US-6503902-B2 | Treatment of neurological disorders related to beta -amyloid production such as Alzheimer's disease and Down's Syndrome. | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-01-07 | — | — | US | disclosed |
| US-6452010-B1 | HYDROXAMIC ACID DERIVATIVES OF CERTAIN CARBOXYLIC ACIDS HAVE BEEN RECOGNIZED AS INHIBITORS OF MATRIX METALLOPROTEINASES | HOFFMANN-LA ROCHE INC. | 2002-09-17 | — | — | US | disclosed |
| US-20020052360-A1 | Hydroxyalkanoylaminolactams and related structures as inhibitors of a beta protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-05-02 | — | — | US | disclosed |
| US-6316633-B1 | CARTILAGE PROTECTIVE AGENTS AND USEFUL IN THE THERAPY AND PROPHYLAXIS OF DEGENERATIVE JOINT DISEASES SUCH AS ATHEROSCLEROSIS | HOFFMAN-LA ROCHE INC. | 2001-11-13 | — | — | US | disclosed |
| US-6197995-B1 | INTERMEDIATES FOR CARTILAGE PROTECTIVE AGENTS USEFUL IN TREATMENT AND PREVENTION OF DEGENERATIVE JOINT DISEASES SUCH AS ATHEROSCLEROSIS | HOFFMAN-LA ROCHE INC. | 2001-03-06 | — | — | US | disclosed |
| EP-1052249-A1 | Process for the preparation of hydroxamic acids | F. HOFFMANN-LA ROCHE AG (CH) | 2000-11-15 | — | — | EP | disclosed |
| US-5952507-A | Process for manufacture of chiral succinic acid derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1999-09-14 | — | — | US | disclosed |
| US-5128448-A | Peptide hormones | HOFFMAN-LA ROCHE INC. (US) | 1992-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132482-A1 | HYDROXYALKANOYLAMINOLACTAMS AND RELATED STRUCTURES AS INHIBITORS OF A BETA PROTEIN PRODUCTION | APP, BACE1, APH1A | LMNA 336/4885MAPK1 696/4885SMN1; SMN2 1435/4885 |
| US-20030166636-A1 | Hydroxyalkanoylaminolactams and related structures as inhibitors of A-beta protein production | APP, APH1A, APH1B | LMNA 359/4885MAPK1 824/4885SMN1; SMN2 1445/4885 |
| US-20020052360-A1 | Hydroxyalkanoylaminolactams and related structures as inhibitors of a beta protein production | APP, APH1A, BACE1 | LMNA 373/4885MAPK1 679/4885SMN1; SMN2 1264/4885 |
| US-20090111793-A1 | HYDROXYALKANOYLAMINOLACTAMS AND RELATED STRUCTURES AS INHIBITORS OF A BETA PROTEIN PRODUCTION | APP, BACE1, APH1A | LMNA 336/4885MAPK1 696/4885SMN1; SMN2 1435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.